A former study has proved LINC01134 displays a high expression in HCC with oxaliplatin (OXA) resistance, and higher LINC01134 expression indicates poorer OXA therapeutic efficacy (Ma et al., 2021). Here, LINC01134 is linked to hepatocellular carcinoma.